10 research outputs found
Impact of statin withdrawal on perceived and objective muscle function.
Background and aimsStatin-associated muscle symptoms (SAMS) are frequently reported. Nevertheless, few data on objective measures of muscle function are available. Recent data suggesting an important nocebo effect with statin use could confound such effects. The objective was to assess if subjective and objective measures of muscle function improve after drug withdrawal in SAMS reporters.MethodsPatients (59 men, 33 women, 50.3±9.6 yrs.) in primary cardiovascular prevention composed three cohorts: statin users with (SAMS, n = 61) or without symptoms (No SAMS, n = 15), and controls (n = 16) (registered at clinicaltrials.gov, NCT01493648). Force (F), endurance (E) and power (P) of the leg extensors (ext) and flexors (fle) and handgrip strength (Fhg) were measured using isokinetic and handheld dynamometers, respectively. A 10-point visual analogue scale (VAS) was used to self-assess SAMS intensity. Measures were taken before and after two months of withdrawal.ResultsFollowing withdrawal, repeated-measures analyses show improvements for the entire cohort in Eext, Efle, Ffle, Pext and Pfle (range +7.2 to +13.3%, all p≤0.02). Post-hoc analyses show these changes to occur notably in SAMS (+8.8 to +16.6%), concurrent with a decrease in subjective perception of effects in SAMS (VAS, from 5.09 to 1.85). Fhg was also improved in SAMS (+4.0 to +6.2%) when compared to No SAMS (-1.7 to -4.2%) (all p = 0.02).ConclusionsWhether suffering from "true" SAMS or nocebo, those who reported SAMS had modest but relevant improvements in muscle function concurrent with a decrease in subjective symptoms intensity after drug withdrawal. Greater attention by clinicians to muscle function in frail statin users appears warranted.Trial registrationThis study is registered in clinicaltrials.gov (NCT01493648)
Significant mitral regurgitation left untreated at the time of aortic valve replacement : a comprehensive review of a frequent entity in the transcatheter aortic valve replacement era.
Significant mitral regurgitation (MR) is frequent in patients with severe aortic stenosis (AS). In these cases,
concomitant mitral valve repair or replacement is usually performed at the time of surgical aortic valve replacement
(SAVR). Transcatheter aortic valve replacement (TAVR) has recently been considered as an alternative for patients at
high or prohibitive surgical risk. However, concomitant significant MR in this setting is typically left untreated. Moderate
to severe MR after aortic valve replacement is therefore a relevant entity in the TAVR era. The purpose of this review is
to present the current knowledge on the clinical impact and post-procedural evolution of concomitant significant MR in
patients with severe AS who have undergone aortic valve replacement (SAVR and TAVR). This information could
contribute to improving both the clinical decision-making process in and management of this challenging group of
patients
Long-term prognostic value and serial changes of plasma N-terminal prohormone B-type natriuretic peptide in patients undergoing transcatheter aortic valve implantation.
Little is known about the usefulness of evaluating cardiac neurohormones in patients undergoing
transcatheter aortic valve implantation (TAVI). The objectives of this study were
to evaluate the baseline values and serial changes of N-terminal prohormone B-type
natriuretic peptide (NT-proBNP) after TAVI, its related factors, and prognostic value. A
total of 333 consecutive patients were included, and baseline, procedural, and follow-up
(median 20 months, interquartile range 9 to 36) data were prospectively collected. Systematic
NT-proBNP measurements were performed at baseline, hospital discharge, 1, 6,
and 12 months, and yearly thereafter. Baseline NT-proBNP values were elevated in 86% of
the patients (median 1,692 pg/ml); lower left ventricular ejection fraction and stroke volume
index, greater left ventricular mass, and renal dysfunction were associated with greater
baseline values (p <0.01 for all). Higher NT-proBNP levels were independently associated
with increased long-term overall and cardiovascular mortalities (p <0.001 for both), with a
baseline cut-off level of w2,000 pg/ml best predicting worse outcomes (p <0.001). At 6- to
12-month follow-up, NT-proBNP levels had decreased (p <0.001) by 23% and remained
stable up to 4-year follow-up. In 39% of the patients, however, there was a lack of
NT-proBNP improvement, mainly related to preprocedural chronic atrial fibrillation, lower
mean transaortic gradient, and moderate-to-severe mitral regurgitation (p <0.01 for all). In
conclusion, most patients undergoing TAVI presented high NT-proBNP levels, and a lack
of improvement was observed in >1/3 of the patients after TAVI. Also, higher NT-proBNP
levels predicted greater overall and cardiac mortalities at a median follow-up of 2 years.
These findings support the implementation of NT-proBNP measurements for the clinical
decision-making process and follow-up of patients undergoing TAVI